Senesco Technologies reported that the FDA has granted orphan-drug designation for the company's lead drug candidate SNS01-T for treatment of both mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).
SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers. Senesco was previously granted orphan drug status for SNS01-T for treatment of multiple myeloma.
For more information visit www.senesco.com.
albert nobbs a star is born oscar nominees oscar nominations 2012 kombucha tea separation of church and state dale earnhardt
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.